Galderma aids Nemluvio launch by expanding evidence base

Swiss skincare specialist Galderma (SIX: GALD) has announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis (AD).

The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and showing sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.

These data from the ARCADIA long-term extension study were presented in a late-breaker abstract at the Revolutionizing Atopic Dermatitis Conference.